LDL-aferees väljendunud hüperkolesteroleemia ravis [PDF]
, 2006 Terapeutiline aferees on meditsiiniline protseduur, mille käigus eemaldatakse ravi otstarbel verest kehaväliselt selle erinevaid komponente. Dialüüs on enim kasutatud ja tuntuim vere puhastamise meetod, sellele on aga edukalt lisandunud hulk teisi ...
Viigimaa, Margus, Välkmann, Reet
core +2 more sources
PCSK9 Inhibitors: The Evolving Future
Health Science Reports, Volume 7, Issue 11, November 2024.ABSTRACT Introduction PCSK9 inhibitors are a novel class of medications that lower LDL cholesterol (LDL‐C) by increasing LDL receptor activity, promoting clearance of LDL‐C from the bloodstream. Over the years, PCSK9 inhibitors have been explored as adjunct therapies to statins or as monotherapy in high‐risk cardiovascular patients.
Bijay Mukesh Jeswani +5 more
wiley +1 more source
Label Distribution Learning [PDF]
arXiv, 2014 Although multi-label learning can deal with many problems with label ambiguity, it does not fit some real applications well where the overall distribution of the importance of the labels matters. This paper proposes a novel learning paradigm named \emph{label distribution learning} (LDL) for such kind of applications.
arxiv
The giant low-density lipoproteins (LDL) accumulation in the multi-layer artery wall model [PDF]
arXiv, 2014 The mathematical, four-layer model of the LDL transport across the arterial wall including the sensitivity of the transport coefficients to the wall shear stress (WSS) is studied. In that model the advection-diffusion equations in porous media are used to determine the LDL concentration profiles in each layer of the arterial wall.
arxiv
In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy
Journal of Lipid Research, 2004 LDL can be subfractionated into buoyant (1.020–1.029 g/ml−1), intermediate (1.030–1.040 g/ml−1), and dense (1.041–1.066 g/ml−1) LDLs. We studied the rebound of these LDL-subfractions after LDL apheresis in seven patients with heterozygous familial ...
H.C. Geiss +4 more
doaj
Eight novel LDL receptor gene mutations among patients under LDL apheresis in Dresden and Leipzig Communicated by Mark H. Paalman Online Citation: Human Mutation, Mutation in Brief #392 (2000) Online http://journals.wiley.com/1059-7794/pdf/mutation/392.pdf [PDF]
, 2001 H. Bochmann +9 more
openalex +2 more sources
LDL‐aférese no tratamento de hipercolesterolemia familiar: experiência do Hospital Santo António
Revista Portuguesa de Cardiologia, 2015 Resumo: Introdução: A hipercolesterolemia manifestada pelos níveis elevados de colesterol das lipoproteínas de baixa densidade constitui um fator de risco major para o desenvolvimento e progressão da doença aterosclerótica prematura.A adsorção direta de
Isabel Palma +8 more
doaj
Lipoprotein apheresis efficacy and challenges: single center experience
Hematology, Transfusion and Cell Therapy, 2022 Introduction: Lipoprotein apheresis (LA) is an extracorporeal therapy which removes apolipoprotein B-containing particles from the circulation. We evaluated techniques and efficiency of lipoprotein apheresis procedures applied to patients with familial ...
Zehra Narlı Özdemir +4 more
doaj
COMPARATIVE EFFECT OF APHERESIS vs ATORVASTATIN/APHERESIS ON MARKERS OF INFLAMMATION IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA [PDF]
Objective: Patients with Familial Hypercholesterolemia (FH) have increased cardiovascular events. Clinical trials have demonstrated that lowering circulating lipid levels by LDL-apheresis has beneficial effects on prognosis.
Bigazzi, Federico +4 more
core
A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study [PDF]
, 2019 Background: Homozygous familial hypercholesterolemia (hoFH) is a rare inherited disorder characterized by extreme elevation of low-density lipoprotein (LDL) cholesterol, accelerated coronary artery disease, and premature death.
Di Giacomo S. +7 more
core +1 more source